Long-Term Safety and Efficacy of Risankizumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: Results from a Phase 2 Open-Label Extension Trial

被引：0
|
作者：
Kim A. Papp
Saskia de Vente
Jiewei Zeng
Mary Flack
Byron Padilla
Stephen K. Tyring
机构：
[1] K Papp Clinical Research and Probity Medical Research,
[2] AbbVie Inc.,undefined
[3] Boehringer Ingelheim Pharmaceuticals,undefined
[4] Inc.,undefined
[5] University of Texas Health Science Center and Center for Clinical Studies,undefined
来源：
Dermatology and Therapy | 2021年 / 11卷
关键词：
Biologic therapy; Interleukin-23; Open-label extension; Psoriasis; Risankizumab;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：487 / 497
页数：10
相关论文
共 50 条
  • [1] Long-Term Safety and Efficacy of Risankizumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: Results from a Phase 2 Open-Label Extension Trial
    Papp, Kim A.
    de Vente, Saskia
    Zeng, Jiewei
    Flack, Mary
    Padilla, Byron
    Tyring, Stephen K.
    [J]. DERMATOLOGY AND THERAPY, 2021, 11 (02) : 487 - 497
  • [2] Tofacitinib in patients with moderate-to-severe chronic plaque psoriasis: long-term safety and efficacy in an open-label extension study
    Valenzuela, F.
    Korman, N. J.
    Bissonnette, R.
    Bakos, N.
    Tsai, T. -F.
    Harper, M. K.
    Ports, W. C.
    Tan, H.
    Tallman, A.
    Valdez, H.
    Gardner, A. C.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2018, 179 (04) : 853 - 862
  • [3] Tofacitinib in patients with moderate to severe chronic plaque psoriasis: 2-year efficacy and safety in an open-label long-term extension study
    Paul, Carle
    Langley, Richard G.
    Valenzuela, Fernando
    Cather, Jennifer
    Gardner, Annie
    Proulx, James
    Tan, Huaming
    Wolk, Robert
    Kaur, Mandeep
    Rottinghaus, Scott
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) : AB278 - AB278
  • [4] Long-term efficacy and safety of risankizumab for the treatment of moderate-to-severe plaque psoriasis: interim analysis of the LIMMitless open-label extension trial beyond 3 years of follow-up
    Papp, K. A.
    Lebwohl, M. G.
    Puig, L.
    Ohtsuki, M.
    Beissert, S.
    Zeng, J.
    Rubant, S.
    Sinvhal, R.
    Zhao, Y.
    Soliman, A. M.
    Alperovich, G.
    Leonardi, C.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2021, 185 (06) : 1135 - 1145
  • [5] Bimekizumab efficacy and safety through 3 years in patients with moderate to severe plaque psoriasis: Long-term results from the BE SURE trial and BE BRIGHT open-label extension
    Sinclair, Rodney
    Thaci, Diamant
    Vender, Ronald
    de Rie, Menno
    Conrad, Curdin
    Soung, Jennifer
    Strober, Bruce
    Wang, Maggie
    Cross, Nancy
    Deherder, Delphine
    Gomez, Natalie Nunez
    Gottlieb, Alice B.
    [J]. AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2023, 64 : 18 - 18
  • [6] Improvement in nail psoriasis in the open-label extension of a phase-2 trial of ixekizumab in patients with moderate-to-severe plaque psoriasis
    McKevitt, N.
    Rich, P.
    Langley, R. G.
    Menter, A.
    Krueger, G.
    Zhu, B.
    Wei, H.
    Cameron, G. S.
    Heffernan, M. P.
    [J]. AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2015, 56 : 50 - 50
  • [7] Improvement in nail psoriasis in the open-label extension period of a phase 2 trial of ixekizumab in patients with moderate-to-severe plaque psoriasis
    Rich, P.
    Langley, R. G.
    Menter, A.
    Krueger, G. G.
    Zhu, B.
    Wei, H.
    Cameron, G. S.
    Heffernan, M. P.
    Holzkaemper, T.
    [J]. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2015, 13 : 135 - 136
  • [8] Safety and efficacy of bimekizumab through 2 years in patients with moderate to severe plaque psoriasis: Long-term results from BE SURE randomised controlled trial and BE BRIGHT open-label extension
    Thaci, Diamant
    Vender, Ronald
    de Rie, Menno
    Conrad, Curdin
    Pariser, David
    Strober, Bruce
    Vanvoorden, Veerle
    Peterson, Luke
    Madden, Cynthia
    De Cuyper, Dirk
    Rubel, Diana
    Kimball, Alexa
    [J]. AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2022, 63 : 14 - 15
  • [9] Efficacy and safety of Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis: Results from the Phase 3 IMMvent trial
    Reich, K.
    Gooderham, M.
    Thaci, D.
    Crowley, J. J.
    Ryan, C.
    Kruger, J. G.
    Tsai, T.
    Flack, M.
    Gu, Y.
    Williams, D. A.
    Thompson, E. H.
    Paul, C.
    [J]. EXPERIMENTAL DERMATOLOGY, 2019, 28 (03) : E24 - E25
  • [10] Long-term safety of risankizumab from 17 clinical trials in patients with moderate-to-severe plaque psoriasis
    Gordon, K. B.
    Lebwohl, M.
    Papp, K. A.
    Bachelez, H.
    Wu, J. J.
    Langley, R. G.
    Blauvelt, A.
    Kaplan, B.
    Shah, M.
    Zhao, Y.
    Sinvhal, R.
    Reich, K.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2022, 186 (03) : 466 - 475
12345